Jessica Fitzwater
Family · Grantsville, WVNPI 1093137226
Payments from drug & device makers
Across 125 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$455
- Lilly USA, LLC$310
- AbbVie$258
- Amarin Pharma, Inc.$219
- AstraZeneca$217
- Abbott$99
- plus $355 from 14 others
What the payments were for
- Food & beverage$1,90199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $455 |
| Lilly USA, LLC | 20 | $310 |
| AbbVie | 12 | $258 |
| Amarin Pharma, Inc. | 17 | $219 |
| AstraZeneca | 13 | $217 |
| Abbott | 5 | $99 |
| Boehringer Ingelheim | 4 | $60 |
| Johnson & Johnson | 3 | $51 |
| Mylan Specialty L.p. | 3 | $50 |
| GSK | 2 | $32 |
| Corcept Therapeutics | 1 | $21 |
| Amgen | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$1,912 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 60 | $75,218 |
| EliquisApixaban | 69 | $57,164 |
| MounjaroTirzepatide | 43 | $47,732 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $47,265 |
| OzempicSemaglutide | 27 | $44,757 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $21,594 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $18,136 |
| VascepaIcosapent Ethyl | 26 | $16,789 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $13,459 |
| FarxigaDapagliflozin Propanediol | 11 | $13,174 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $12,385 |
| MyrbetriqMirabegron | 12 | $4,873 |
| SantylCollagenase Clostridium Hist. | 11 | $3,752 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $3,299 |
| Atorvastatin Calcium | 194 | $1,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $60 | $75,21860 claims |
| Lilly USA, LLCMounjaro | $310 | $47,73243 claims |
| Novo NordiskOzempic | $455 | $44,75727 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $32 | $39,73043 claims |
| AstraZenecaFarxiga | $217 | $13,17411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.
Other family in Grantsville
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.